Results 51 to 60 of about 156,135 (207)

Abrupt Cessation of One-Year Clopidogrel Treatment Is Not Associated With Thrombotic Events

Journal of Pharmacological Sciences, 2011
.: We aimed to examine the rate of thrombotic events after discontinuation of one year clopidogrel therapy in patients with implanted coronary stent, and to determine platelet aggregability by multiple electrode analyzer after cessation of clopidogrel ...
Nina Djukanovic, Zoran Todorovic, Slobodan Obradovic, Danijela Zamaklar-Trifunovic, Srdjana Njegomirovic, Nataša M. Milic, Milica Prostran, Miodrag Ostojic   +7 more
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

Primary Percutaneous Coronary Intervention Guided by High‐Definition Intravascular Ultrasound (The SPECTRUM Study)

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Limited data are available on the use of intravascular ultrasound (IVUS) in patients presenting with ST‐segment elevation myocardial infarction (STEMI). Aims This study aimed to assess the impact of IVUS‐guided primary percutaneous coronary intervention (PCI).
Frederik T. W. Groenland, Annemieke C. Ziedses des Plantes, Tara Neleman, Jurgen M. R. Ligthart, Karen T. Witberg, Rutger‐Jan Nuis, Jeroen M. Wilschut, Roberto Diletti, Wijnand K. den Dekker, Isabella Kardys, Paul Cummins, Karim D. Mahmoud, Nicolas M. Van Mieghem, Joost Daemen   +13 more
wiley   +1 more source

A Large Retrospective Study to Evaluate Utility of Zephyr Covered Stent in Transcatheter Closure of Sinus Venosus Defects

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter closure (TCC) of sinus venosus defects (SVD) using balloon‐expandable covered stents is an emerging alternative to surgery. ZephyrCS (Sahajanand Laser Technologies, Gandhinagar, India) is available in long lengths to suit SVD closure.
Pramod Sagar, Puthiyedath Thejaswi, Kothandam Sivakumar, Praveen Ashok Kumar   +3 more
wiley   +1 more source

Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis.

PLoS ONE, 2011
The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug.
Analia E Garcia, Sripal R Mada, Mario C Rico, Raul A Dela Cadena, Satya P Kunapuli   +4 more
doaj   +1 more source

The Role of Clopidogrel in 2020: A Reappraisal

Cardiovascular Therapeutics, 2020
Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD).
Giuseppe Patti, Giuseppe Micieli, Claudio Cimminiello, Leonardo Bolognese   +3 more
doaj   +1 more source

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.

PLoS ONE, 2013
BackgroundThe efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy. We investigated the efficacy and safety of
Tsung-Hsien Lin, Wen-Ter Lai, Ho-Tsung Hsin, Ai-Hsien Li, Chun-Li Wang, Chi-Tai Kuo, Juey-Jen Hwang, Fu-Tien Chiang, Shu-Chen Chang, ACS Full Spectrum Registry Investigators   +9 more
doaj   +1 more source

Temporal Trends and Prognosis in Rotational Atherectomy: A Comparison of Contemporary and Traditional Eras

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Rotational atherectomy (RA) has undergone considerable technical modernization in recent years. This study evaluated whether RA performed in the contemporary era was associated with superior cardiovascular outcomes compared with the traditional era. Aims To compare the clinical characteristics and cardiovascular outcomes of patients
Ravi Vazirani, Gonzalo García‐Martí, Andrés Provencio‐Regidor, Irene Serrano‐García, Adrián Jerónimo‐Baza, Alejandro Travieso, Gabriela Tirado‐Conte, Fernando Macaya‐Ten, Hernán Mejía‐Rentería, Pablo Salinas, Luis Nombela‐Franco, Pilar Jiménez‐Quevedo, Nieves Gonzalo, Javier Escaned, Antonio Fernández‐Ortiz, Iván J. Núñez‐Gil   +15 more
wiley   +1 more source

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

CPT: Pharmacometrics & Systems Pharmacology
Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects.
Yun Seob Jung, Byung Hak Jin, Min Soo Park, Choon Ok Kim, Dongwoo Chae   +4 more
doaj   +1 more source